Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula. Ophthotech Corporation has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach and novel gene delivery technologies to target retinal diseases. The company was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPHT
CUSIPN/A
Phone212-845-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio18.62
Quick Ratio18.62
Price-To-Earnings
Trailing P/E Ratio0.93
Forward P/E Ratio-1.77
P/E GrowthN/A
Sales & Book Value
Annual Sales$209.98 million
Price / Sales0.50
Cash Flow$3.0968 per share
Price / Cash0.93
Book Value$1.06 per share
Price / Book2.72
Profitability
EPS (Most Recent Fiscal Year)$3.17
Net Income$114.20 million
Net Margins26.69%
Return on Equity-1,485.62%
Return on Assets79.93%
Miscellaneous
Employees38
Outstanding Shares36,190,000
Ophthotech (NASDAQ:OPHT) Frequently Asked Questions
What is Ophthotech's stock symbol?
Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."
How were Ophthotech's earnings last quarter?
Ophthotech Corp (NASDAQ:OPHT) posted its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.04. Ophthotech had a net margin of 26.69% and a negative return on equity of 1,485.62%. View Ophthotech's Earnings History.
When is Ophthotech's next earnings date?
What price target have analysts set for OPHT?
3 analysts have issued 12 month target prices for Ophthotech's shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Ophthotech's stock price to reach $4.00 in the next year. View Analyst Ratings for Ophthotech.
What are Wall Street analysts saying about Ophthotech stock?
Here are some recent quotes from research analysts about Ophthotech stock:
- 1. Chardan Capital analysts commented, "We understand previous attempts at this indication, e.g. via RhoNova (acquired by 2016), required 2 vectors (one to block the mutant protein and one to produce normal protein), which requires higher vector doses and was technically difficult. Work in mice has demonstrated a single vector construct can improve both retinal structure and function; and, the company indicated studies in large animal (i.e. canine) models have yielded promising results, which management expects will be published soon. A sponsored research agreement was also established between for continued preclinical and natural history studies. Ophthotech plans to initiate IND-enabling studies with the goal of beginning a phase I/II trial in early 2020." (6/13/2018)
- 2. According to Zacks Investment Research, "Ophthotech reported narrower-than-expected loss in the first quarter compared with the year-ago period. The company is focused on development of Zimura, after the failure of Fovista program. The company has reassessed its wet age-related macular degeneration (AMD) program and is developing Zimura in combination with anti-VEGF therapy. The company also collaborated with other companies to develop Zimura in combination studies. With no approved products, the company’s revenues are dependent on collaborations, which may be affected by pipeline setbacks. In a major setback, Novartis terminated its agreement following the failure of Fovista in three phase III program on Fovista. The company lost a major source of revenues. Shares have underperformed the industry so far this year." (5/14/2018)
Who are some of Ophthotech's key competitors?
Some companies that are related to Ophthotech include Dermira (DERM), GTX (GTXI), Syros Pharmaceuticals (SYRS), Achillion Pharmaceuticals (ACHN), Savara (SVRA), American Brivision (Holding) (ABVC), Albireo Pharma (ALBO), Unum Therapeutics (UMRX), Bellicum Pharmaceuticals (BLCM), Evelo Biosciences (EVLO), Arbutus Biopharma (ABUS), Corvus Pharmaceuticals (CRVS), Aquinox Pharmaceuticals (AQXP), Axovant Sciences (AXON) and Catalyst Pharmaceuticals (CPRX).
Who are Ophthotech's key executives?
Ophthotech's management team includes the folowing people:
- Dr. David R. Guyer, Exec. Chairman (Age 58)
- Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 62)
- Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 57)
- Dr. Michael J. Ross, Director (Age 69)
- Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 52)
Has Ophthotech been receiving favorable news coverage?
News stories about OPHT stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Ophthotech's major shareholders?
Ophthotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tamarack Advisers LP (2.35%), Dimensional Fund Advisors LP (1.56%), Spark Investment Management LLC (1.18%), Municipal Employees Retirement System of Michigan (1.06%), Millennium Management LLC (0.94%) and GSA Capital Partners LLP (0.62%). Company insiders that own Ophthotech stock include A/S Novo, Barbara A Wood, David E Redlick, David Francis Carroll, David R Guyer, Glenn Sblendorio, Henric Bjorn Bjarke, Keith Westby and Samir Chandrakant Patel. View Institutional Ownership Trends for Ophthotech.
Which major investors are selling Ophthotech stock?
OPHT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Russell Investments Group Ltd. and A.R.T. Advisors LLC. Company insiders that have sold Ophthotech company stock in the last year include Barbara A Wood, David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby. View Insider Buying and Selling for Ophthotech.
Which major investors are buying Ophthotech stock?
OPHT stock was acquired by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Spark Investment Management LLC, Tamarack Advisers LP, Alambic Investment Management L.P. and Northern Trust Corp. View Insider Buying and Selling for Ophthotech.
How do I buy shares of Ophthotech?
Shares of OPHT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ophthotech's stock price today?
One share of OPHT stock can currently be purchased for approximately $2.88.
How big of a company is Ophthotech?
Ophthotech has a market capitalization of $109.29 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $114.20 million in net income (profit) each year or $3.17 on an earnings per share basis. Ophthotech employs 38 workers across the globe.
How can I contact Ophthotech?
Ophthotech's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected]
MarketBeat Community Rating for Ophthotech (OPHT)
MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days.
